Fortrea Holdings Inc. has announced a strategic collaboration with SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products. The partnership aims to accelerate the development and delivery of cell and gene therapies by harmonizing clinical trial logistics with manufacturing readiness. By combining Fortrea's global clinical development expertise with SCTbio's manufacturing and release capabilities, the collaboration seeks to streamline planning, reduce risks, and expedite the path from early-stage development to commercialization for advanced therapies. This joint effort is designed to set a new standard for operational excellence in the field of cell and gene therapy development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortrea Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596607-en) on December 04, 2025, and is solely responsible for the information contained therein.